Teleflex Incorporated (NYSE: TFX) has unveiled groundbreaking results from the CLEAR study, the first head-to-head randomized ...

A new Global Urological Device Market Report offers critical insights for CEOs, CFOs, product and marketing managers in the ...

Do you ever you wake up once, twice or more during the night to pee? These nighttime wakeups are common. Here’s how to solve ...

China: A recent study published in BMC Urology highlighted PSA density (PSAD) as an effective predictor of prostate cancer in ...

Teleflex today announced new data highlighting the success of its UroLift benign prostatic hyperplasia (BPH) treatment system ...

Using a high-pressure water jet to operate on an enlarged prostate can better preserve the ability to ejaculate, compared ...

About Profound Medical Corp. Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. Profound is ...

For men with benign prostatic hyperplasia (BPH), transurethral Holmium Laser of the Prostate (HoLEP) with Double-n Technology shows promise for improving urinary symptoms while better preserving ...

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that new findings from the CLEAR study were presented at the 40th Annual European Association of ...

Using a high-pressure water jet to operate on an enlarged prostate can better preserve the ability to ejaculate, compared ...

"Our strong fourth quarter performance reflects our continued progress in establishing Focal One Robotic HIFU as a mainstream treatment option for the management of prostate cancer,” said Ryan Rhodes, ...

UCL,child penalty,diagnosisHere are the top medical news for the day:Study Highlights 10% Earnings Decline in Women Four ...